Clinical Trial Update: A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigating the efficacy and safety of Riliprubart versus the usual IVIg treatment in chronic inflammatory demyelinating polyneuropat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)
• Riliprubart

Snippet

Sponsor: Sanofi | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Status: RECRUITING